The adoptive transfer of CAR-T cells, which are modified T cells expressing chimeric antigen receptors (CARs), to target B cell maturation antigen (BCMA) has demonstrated impressive results in treating relapsed/refractory multiple myeloma. Although BCMA CAR-T therapy induces certain complications in some patients, idiopathic thrombocytopenic purpura (ITP) has not been reported as one of them. To the best of our knowledge, this is the first report of the successful treatment of ITP that arose in a relapsed/refractory multiple myeloma patient following anti-BCMA CAR-T cell infusion. Herein, we describe this relatively uncommon complication and provide guidance on its treatment.

CAR-T细胞是表达嵌合抗原受体（CARs）的修饰T细胞向目标B细胞成熟抗原（BCMA）的过继转移，在治疗复发/难治性多发性骨髓瘤中已显示出令人印象深刻的结果。尽管BCMA CAR-T治疗在某些患者中引起某些并发症，但尚未报道特发性血小板减少性紫癜（ITP）其中之一。据我们所知，这是首次成功治疗ITP的报告，该ITP是在抗BCMA CAR-T细胞输注后复发/难治的多发性骨髓瘤患者中产生的。本文中，我们描述了这种相对罕见的并发症，并为其治疗提供了指导。